Belgium, 15 June 2020: Fund+, an investment firm focused on innovative European Life Sciences companies, today announced changes to the Board following the AGM. Luc Debruyne and Gérard Lamarche have been appointed to the Board of Fund+.
In accordance with the Company’s governance charter, Honorary Chairman Désiré Collen, Arnoud de Pret, Pierre Drion and Hilde Laga have stepped down from the Board following expiry of the term of their office. Désiré Collen, Honorary Chairman, will remain as a Board observer.
Chris Buyse, Managing Partner and Executive Board Member of Fund+, commented: “We are delighted to welcome Luc Debruyne and Gérard Lamarche to the Board. Luc Debruyne brings outstanding scientific and commercialisation experience from GSK, where he led the global vaccines business; and a wealth of international expertise having worked across Europe and managed businesses globally including significant focus and experience in the US. Gérard Lamarche will leverage his track record of successful transactions and brings an invaluable perspective to the Board following an impressive track record of strategic roles at well-established industrial companies.